Your browser doesn't support javascript.
loading
Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
Anand, Sai Priya; Ding, Shilei; Tolbert, William D; Prévost, Jérémie; Richard, Jonathan; Gil, Hwi Min; Gendron-Lepage, Gabrielle; Cheung, Wing-Fai; Wang, Haifeng; Pastora, Rebecca; Saxena, Hirak; Wakarchuk, Warren; Medjahed, Halima; Wines, Bruce D; Hogarth, Mark; Shaw, George M; Martin, Malcom A; Burton, Dennis R; Hangartner, Lars; Evans, David T; Pazgier, Marzena; Cossar, Doug; McLean, Michael D; Finzi, Andrés.
Afiliação
  • Anand SP; Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Ding S; Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
  • Tolbert WD; Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Prévost J; Infectious Diseases Division, Department of Medicine of Uniformed Services University of the Health Sciencesgrid.265436.0, Bethesda, Maryland, USA.
  • Richard J; Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Gil HM; Département de Microbiologie, Infectiologie, et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
  • Gendron-Lepage G; Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Cheung WF; Département de Microbiologie, Infectiologie, et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
  • Wang H; Wisconsin National Primate Research Center, University of Wisconsin, Madison, Wisconsin, USA.
  • Pastora R; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Saxena H; Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Wakarchuk W; PlantForm Corporation, Toronto, Ontario, Canada.
  • Medjahed H; PlantForm Corporation, Toronto, Ontario, Canada.
  • Wines BD; PlantForm Corporation, Toronto, Ontario, Canada.
  • Hogarth M; Department of Chemistry and Biology, Ryerson Universitygrid.68312.3e, Toronto, Ontario, Canada.
  • Shaw GM; Department of Chemistry and Biology, Ryerson Universitygrid.68312.3e, Toronto, Ontario, Canada.
  • Martin MA; Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Burton DR; Immune Therapies Group, Burnet Institutegrid.1056.2, Melbourne, VIC, Australia.
  • Hangartner L; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
  • Evans DT; Department of Immunology and Pathology Monash University, Melbourne, VIC, Australia.
  • Pazgier M; Immune Therapies Group, Burnet Institutegrid.1056.2, Melbourne, VIC, Australia.
  • Cossar D; Department of Clinical Pathology, University of Melbourne, Melbourne, VIC, Australia.
  • McLean MD; Department of Immunology and Pathology Monash University, Melbourne, VIC, Australia.
  • Finzi A; Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Virol ; 95(18): e0079621, 2021 08 25.
Article em En | MEDLINE | ID: mdl-34232070
The activity of broadly neutralizing antibodies (bNAbs) targeting HIV-1 depends on pleiotropic functions, including viral neutralization and the elimination of HIV-1-infected cells. Several in vivo studies have suggested that passive administration of bNAbs represents a valuable strategy for the prevention or treatment of HIV-1. In addition, different strategies are currently being tested to scale up the production of bNAbs to obtain the large quantities of antibodies required for clinical trials. Production of antibodies in plants permits low-cost and large-scale production of valuable therapeutics; furthermore, pertinent to this work, it also includes an advanced glycoengineering platform. In this study, we used Nicotiana benthamiana to produce different Fc-glycovariants of a potent bNAb, PGT121, with near-homogeneous profiles and evaluated their antiviral activities. Structural analyses identified a close similarity in overall structure and glycosylation patterns of Fc regions for these plant-derived Abs and mammalian cell-derived Abs. When tested for Fc-effector activities, afucosylated PGT121 showed significantly enhanced FcγRIIIa interaction and antibody dependent cellular cytotoxicity (ADCC) against primary HIV-1-infected cells, both in vitro and ex vivo. However, the overall galactosylation profiles of plant PGT121 did not affect ADCC activities against infected primary CD4+ T cells. Our results suggest that the abrogation of the Fc N-linked glycan fucosylation of PGT121 is a worthwhile strategy to boost its Fc-effector functionality. IMPORTANCE PGT121 is a highly potent bNAb and its antiviral activities for HIV-1 prevention and therapy are currently being evaluated in clinical trials. The importance of its Fc-effector functions in clearing HIV-1-infected cells is also under investigation. Our results highlight enhanced Fc-effector activities of afucosylated PGT121 MAbs that could be important in a therapeutic context to accelerate infected cell clearance and slow disease progression. Future studies to evaluate the potential of plant-produced afucosylated PGT121 in controlling HIV-1 replication in vivo are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polissacarídeos / Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Anticorpos Neutralizantes / Anticorpos Monoclonais / Citotoxicidade Celular Dependente de Anticorpos Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polissacarídeos / Anticorpos Anti-HIV / Infecções por HIV / HIV-1 / Anticorpos Neutralizantes / Anticorpos Monoclonais / Citotoxicidade Celular Dependente de Anticorpos Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article